Scholarlink

<p>The use of glucocorticoids in systemic sclerosis (SSc) is restricted due to adverse effects. Despite this, a large proportion of patients still use these medications. Their pharmacological effects on the disease are not completely known; few studies have explored them, and the results are controversial. Thus, the present study aimed to investigate the immunomodulatory and antifibrotic activity of Dexamethasone (Dex) in SSc. The effects were evaluated in CD4 + T lymphocytes and macrophages from 20 SSc patients and 10 healthy volunteers and in a murine model of SSc. Cytokines (IL-4, IL-6, IL-13, IL-17A, and TNF) and chemokines (RANTES, IL-8, MIG, and IP-10) were quantified by sandwich enzyme-linked immunosorbent assay (ELISA) or cytometric bead array (CBA) in cell culture supernatant. Balb/c mice received intradermal injections of hypochlorous acid (HOCl) and treatment with Dex (1&#xa0;mg/kg) by intraperitoneal injections for 6&#xa0;weeks. RT-qPCR and histological analysis assessed dermal and pulmonary fibrosis. In the supernatant of CD4 + T lymphocytes, Dex reduced the secretion of IL-4 and IL-13 (<i>p</i> &lt; 0.0001 for both), IL-6 (<i>p</i> = 0.0023) and TNF (<i>p</i> = 0.0005), in addition to the chemokines IP-10, MIG, RANTES, IL-8 (<i>p</i> &lt; 0.0001 for all). Furthermore, Dex treatment SSc mice significantly reduced dermal thickening (<i>p</i> &lt; 0.0001), mRNA expression of Col1a1 (<i>p</i> = 0.002), Tgfβ1 (<i>p</i> &lt; 0.0001) and Acta2 (<i>p</i> &lt; 0.0001) in the skin, and Tgfβ1 (<i>p</i> = 0.005) in the lungs. Furthermore, it reduced IL-4 secretion (<i>p</i> = 0.02) in the splenocyte culture supernatant. In summary, Dex showed immunomodulatory and antifibrotic effects in SSc, evidencing its actions in treating the disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dexamethasone modulates cytokine and chemokine secretion by CD4 + T cells from SSc patients and exerts antifibrotic effects in HOCl-induced SSc mice

  • 期刊论文

  • 发表日期：

    2025年11月19日

查看全文
  • Maria Eduarda de Oliveira Gonçalves,
  • Anderson Rodrigues de Almeida,
  • Andréa Tavares Dantas,
  • Karen Steffani Silva Florencio,
  • Júlia Roberta da Silva Ferreira,
  • Felipe Henrique dos Santos Barbosa,
  • Ryan Cordeiro Silva,
  • Anderson Arnaldo da Silva,
  • Daniel Neri da Matta,
  • Angela Luzia Branco Pinto Duarte,
  • Moacyr Jesus Barreto de Melo Rêgo,
  • Michelly Cristiny Pereira,
  • Maira Galdino da Rocha Pitta

摘要

The use of glucocorticoids in systemic sclerosis (SSc) is restricted due to adverse effects. Despite this, a large proportion of patients still use these medications. Their pharmacological effects on the disease are not completely known; few studies have explored them, and the results are controversial. Thus, the present study aimed to investigate the immunomodulatory and antifibrotic activity of Dexamethasone (Dex) in SSc. The effects were evaluated in CD4 + T lymphocytes and macrophages from 20 SSc patients and 10 healthy volunteers and in a murine model of SSc. Cytokines (IL-4, IL-6, IL-13, IL-17A, and TNF) and chemokines (RANTES, IL-8, MIG, and IP-10) were quantified by sandwich enzyme-linked immunosorbent assay (ELISA) or cytometric bead array (CBA) in cell culture supernatant. Balb/c mice received intradermal injections of hypochlorous acid (HOCl) and treatment with Dex (1 mg/kg) by intraperitoneal injections for 6 weeks. RT-qPCR and histological analysis assessed dermal and pulmonary fibrosis. In the supernatant of CD4 + T lymphocytes, Dex reduced the secretion of IL-4 and IL-13 (p < 0.0001 for both), IL-6 (p = 0.0023) and TNF (p = 0.0005), in addition to the chemokines IP-10, MIG, RANTES, IL-8 (p < 0.0001 for all). Furthermore, Dex treatment SSc mice significantly reduced dermal thickening (p < 0.0001), mRNA expression of Col1a1 (p = 0.002), Tgfβ1 (p < 0.0001) and Acta2 (p < 0.0001) in the skin, and Tgfβ1 (p = 0.005) in the lungs. Furthermore, it reduced IL-4 secretion (p = 0.02) in the splenocyte culture supernatant. In summary, Dex showed immunomodulatory and antifibrotic effects in SSc, evidencing its actions in treating the disease.